

Pursuant to the provisions of article 228 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("**Grifols**") hereby informs about the following

## RELEVANT EVENT

Grifols, through its 100% subsidiary Grifols Innovation and New Technologies Limited ("**GIANT**"), has acquired a 43.96% shareholding in GigaGen Inc. ("**GigaGen**"), a company based in San Francisco (USA) for the amount of \$35M.

GIANT and GigaGen have also entered into a Research and Collaboration Agreement whereby in exchange of a collaboration fee of \$15M in the aggregate, GigaGen will commit to carry out research activities to develop recombinant polyclonal immunoglobulin therapies derived from human B cells for the treatment of human diseases.

GigaGen is a pre-clinical Biotherapeutics company, based in San Francisco, dedicated to using human B-cells, which are the immune cells specialized in the production of antibodies, to capture the whole genetic diversity of these antibodies and to transform this into therapies for the treatment of severe diseases.

In Barcelona, on 5 July 2017

---

Nuria Martín Barnés  
Secretary to the Board of Directors